Lupin receives EIR from USFDA for Pithampur Unit-2 Manufacturing Facility

11 Jul 2023 Evaluate

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Pithampur Unit-2 manufacturing facility that manufactures oral solids and ophthalmic dosage forms. The EIR was issued post the last inspection of the facility conducted from March 21 to March 29, 2023. The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI). 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2130.05 11.80 (0.56%)
19-Dec-2025 10:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1747.40
Dr. Reddys Lab 1280.95
Cipla 1508.25
Zydus Lifesciences 916.75
Lupin 2130.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×